Imugene (Australia) Today
| IMU Stock | 0.04 0 2.56% |
Performance0 of 100
| Odds Of DistressOver 72
|
Imugene is selling for under 0.038 as of the 2nd of December 2024; that is 2.56 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.038. Imugene has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Imugene are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Imugene is entity of Australia. It is traded as Stock on AU exchange. The company has 7.57 B outstanding shares. More on Imugene
Moving together with Imugene Stock
Moving against Imugene Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Imugene Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Imugene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Imugene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Executive Chairman | BA ASiA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Imugene's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Imugene's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsImugene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Imugene's financial leverage. It provides some insight into what part of Imugene's total assets is financed by creditors.
| |||||
Imugene (IMU) is traded on Australian Securities Exchange in Australia and employs 12 people. Imugene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 295.12 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Imugene's market, we take the total number of its shares issued and multiply it by Imugene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Imugene operates under Biotechnology sector and is part of Health Care industry. The entity has 7.57 B outstanding shares.
Imugene has accumulated about 49.54 M in cash with (97.32 M) of positive cash flow from operations.
Check Imugene Probability Of Bankruptcy
Ownership AllocationImugene has a total of 7.57 Billion outstanding shares. Imugene retains 14.38 (percent) of its outstanding shares held by insiders and 6.6 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Imugene Ownership Details
Imugene Risk Profiles
Although Imugene's alpha and beta are two of the key measurements used to evaluate Imugene's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.96 | |||
| Standard Deviation | 3.88 | |||
| Variance | 15.04 | |||
| Risk Adjusted Performance | (0.12) |
Imugene Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Imugene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Imugene Corporate Management
Elected by the shareholders, the Imugene's board of directors comprises two types of representatives: Imugene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imugene. The board's role is to monitor Imugene's management team and ensure that shareholders' interests are well served. Imugene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imugene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leslie Chong | MD CEO | Profile | |
| Ursula McCurry | Senior Operations | Profile | |
| MD Woodard | Chief Officer | Profile | |
| John Byon | Senior Development | Profile | |
| Bradley Glover | Chief Officer | Profile | |
| Bradley MBA | Chief Officer | Profile |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.